‘Demystify’ Pricing, Say UK Parliamentarians
Executive Summary
UK members of parliament have called on pharmaceutical companies to be more transparent in their pricing process and to improve the way they gather and present data for health technology appraisals. They also say that industry rebates should be ring fenced to fund new medicines.